Inhibitory effect of 5,8,11-eicosatrienoic acid on angiogenesis

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 86, Issue 6, 2012, Pages 221-224

  Hamazaki, T ^a,b   Nagasawa, T ^a   Hamazaki, K ^a   Itomura, M ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b Toyama Jonan Onsen Daini Hospital   (Japan)

Author keywords

Arachidonic acid; Cartilage; Co culture; Eicosapentaenoic acid; Eicosatrienoic acid; Vascular endothelial growth factor

Indexed keywords

5,8,11 ICOSATRIENOIC ACID; ARACHIDONIC ACID; DIHOMO GAMMA LINOLENIC ACID; ICOSAPENTAENOIC ACID; ICOSATRIENOIC ACID; N 3 ICOSATRIENOIC ACID; OLEIC ACID; SURAMIN; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ANTIANGIOGENIC ACTIVITY; ARTICLE; COCULTURE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; FATTY ACID ANALYSIS; FATTY ACID TRANSPORT; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; NEOVASCULARIZATION (PATHOLOGY); OSSIFICATION; PRIORITY JOURNAL; UMBILICAL VEIN ENDOTHELIAL CELL;

8,11,14-EICOSATRIENOIC ACID; ANGIOGENESIS INHIBITORS; ARACHIDONIC ACID; COCULTURE TECHNIQUES; EICOSAPENTAENOIC ACID; FIBROBLASTS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84861895758     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2012.04.004     Document Type: Article

References (20)

1. Adkisson H.D., Risener F.S., Zarrinkar P.P., Walla M.D., Christie W.W., Wuthier R.E. Unique fatty acid composition of normal cartilage: discovery of high levels of n-9 eicosatrienoic acid and low levels of n-6 polyunsaturated fatty acids. FASEB J. 1991, 5:344-353.
2. Cleland K.A., James M.J., Neumann M.A., Gibson R.A., Cleland L.G. Differences in fatty acid composition of immature and mature articular cartilage in humans and sheep. Lipids 1995, 30:949-953.
3. Hamazaki T., Suzuki N., Widyowati R., et al. The depressive effects of 5,8,11-eicosatrienoic acid (20:3n-9) on osteoblasts. Lipids 2009, 44:97-102.
4. Takigawa M., Pan H.O., Enomoto M., et al. A clonal human chondrosarcoma cell line produces an anti-angiogenic antitumor factor. Anticancer Res. 1990, 10:311-315.
5. Moses M.A., Sudhalter J., Langer R. Isolation and characterization of an inhibitor of neovascularization from scapular chondrocytes. J. Cell Biol. 1992, 119:475-482.
6. Johnson M.D., Kim H.R., Chesler L., Tsao-Wu G., Bouck N., Polverini P.J. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J. Cell Physiol. 1994, 160:194-202.
7. Moses M.A., Wiederschain D., Wu I., et al. Troponin I is present in human cartilage and inhibits angiogenesis. Proc. Natl. Acad. Sci. USA 1999, 96:2645-2650.
8. Liu N., Lapcevich R.K., Underhill C.B., et al. Metastatin: a hyaluronan-binding complex from cartilage that inhibits tumor growth. Cancer Res. 2001, 61:1022-1028.
9. Kusafuka K., Hiraki Y., Shukunami C., Kayano T., Takemura T. Cartilage-specific matrix protein, chondromodulin-I (ChM-I), is a strong angio-inhibitor in endochondral ossification of human neonatal vertebral tissues in vivo: relationship with angiogenic factors in the cartilage. Acta Histochem. 2002, 104:167-175.
10. Yoshioka M., Yuasa S., Matsumura K., et al. Chondromodulin-I maintains cardiac valvular function by preventing angiogenesis. Nat. Med. 2006, 12:1151-1159.
11. Bishop E.T., Graham T.B., Bloor S., Broom I.J., Hendry N.F.K., Wheatley D.N. An in vitro model of angiogenesis: basic features. Angiogenesis 1999, 3:335-344.
12. Webler A.C., Michaelis U.R., Popp R., et al. Epoxyeicosatrienoic acids are part of the VEGF-activated signaling cascade leading to angiogenesis. Am. J. Physiol. Cell Physiol. 2008, 295:C1292-1301.
13. Spector A.A. Arachidonic acid cytochrome P450 epoxygenase pathway. J. Lipid Res. 2009, 50:S52-S56.
14. Toomey D.P., Murphy J.F., Conlon K.C. Cox-2, VEGF and tumour angiogenesis. Surgeon 2009, 7:174-180.
15. Hatazawa R., Tanaka A., Tanigami M., et al. Cyclooxygenase-2/prostaglandin E2 accelerates the healing of gastric ulcers via EP4 receptors. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 293:G788-797.
16. James M.J., Gibson R.A., Cleland L.G. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am. J. Clin. Nutr. 2000, 71(1 Suppl):343S-348S.
17. Lenz H-J T. Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer. Gastroenterology 2010, 138:2163-2176. Winder.
18. El-Mollayess G.M., Noureddine B.N., Bashshur.Z.F. Bevacizumab and neovascular age related macular degeneration: pathogenesis and treatment. Semin. Ophthalmol. 2011, 26:69-76.
19. Nicholson B.P., Schachat A.P. A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol. 2010, 248:915-930.
20. Cleland L.G., Neumann M.A., Gibson R.A., Hamazaki T., Akimoto K., James M.J. Effect of dietary n-9 eicosatrienoic acid on the fatty acid composition of plasma lipid fractions and tissue phospholipids. Lipids 1996, 31:829-837.